Tokyo Tape
Sign in
← H.U. Group Holdings

Half-year report · Q2

4544.TEDINET S100UPH6
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥120.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥236.9bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥116.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥956m2024-04-01 → 2024-09-30Cons.Operating income
Operating income−¥1.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥1.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income−¥7.2bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.6bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥1.6bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax−¥1.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥821m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥821m2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥291.4bnat 2024-09-30Cons.Assets
Total assets¥290.8bnat 2024-03-31Cons.Assets
Total assets¥284.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥155.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥148.3bnat 2024-03-31Cons.Liabilities
Net assets / equity¥136.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥142.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥150.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥47.0bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥39.9bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥47.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥39.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.6bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥9.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥16.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥10.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-14.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-132.772023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio46.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio49.0%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio52.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥2.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥76.7bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥76.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥205m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥31.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥29.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2024-04-01 → 2024-09-30¥14.5bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2024-04-01 → 2024-09-30¥14.4bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥9m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2024-04-01 → 2024-09-30¥879m
—segment totalrevenue2024-04-01 → 2024-09-30¥122.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥120.0bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.4bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.5bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥2.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥72.4bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥72.3bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥74m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥6.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥33.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-09-30¥564m
—segment totalrevenue2023-04-01 → 2023-09-30¥119.6bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥116.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 536
ItemContextValueUnit
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration716000000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration-511000000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-7089000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration7070000000JPY
Cash and cash equivalentsPrior2YearInstant44185000000JPY
Cash and cash equivalentsPrior1YearInstant39946000000JPY
Cash and cash equivalentsPrior1QuarterInstant37096000000JPY
Cash and cash equivalentsCurrentQuarterInstant47017000000JPY
Salaries and bonuses sgaPrior1YTDDuration5614000000JPY
Salaries and bonuses sgaCurrentYTDDuration5735000000JPY
Provision for bonuses sgaPrior1YTDDuration2211000000JPY
Provision for bonuses sgaCurrentYTDDuration2181000000JPY
Retirement benefit expenses sgaPrior1YTDDuration458000000JPY
Retirement benefit expenses sgaCurrentYTDDuration525000000JPY
Depreciation sgaPrior1YTDDuration2706000000JPY
Depreciation sgaCurrentYTDDuration2673000000JPY
Amortization of goodwill sgaPrior1YTDDuration145000000JPY
Amortization of goodwill sgaCurrentYTDDuration230000000JPY
Commission fee sgaPrior1YTDDuration7459000000JPY
Commission fee sgaCurrentYTDDuration6369000000JPY
Research and development expenses sgaPrior1YTDDuration5119000000JPY
Research and development expenses sgaCurrentYTDDuration5187000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember72291000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember30223000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember14028000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember116543000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration116543000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember74000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember2980000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember3000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember3058000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-3058000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember72366000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember33203000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember14032000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember119602000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-3058000000JPY
Net salesPrior1YTDDuration116543000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember-6190000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember6812000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember564000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember1186000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-2755000000JPY
Operating incomePrior1YTDDuration-1569000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember76518000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember29019000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember14448000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember119987000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass